Galectin Therapeutics Inc. (GALT)

[Chess Master]

Atopic Dermatitis is basically a less severe form of psoriasis. See the same mechanism of action is probably at work here. So the issue is the intravenous dosing. If we can get this to a subcutaneous injection or perhaps get this into a crème think of the potential. Now none of the wizards at the top of this company seem bright enough to come up with this idea. All they could come up with hey lets hire a consulting firm to find a deal with pharma. Here's what we know - that is simply a waste of time. What they need is a new trial designer and perhaps an animal study which they certainly could afford to figure out the best dosage to use in a phase II study for Atopic Dermatitis which is essentially a less severe form of psoriasis that seems to be working quite well. And since its an unmet medical need they wont be bound by this crazy 75 PASI number. I wouldn't be surprised if they upped the dosage if everyone didn't get the PASI of 75. It was just such a poorly designed trial. I mean 10 people really?